Compare Ascendis Pharma A/S (ASND) vs TJX Companies Inc (TJX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs TJX Companies Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while TJX Companies Inc trades at $151.56 (market cap $167.19B). The key difference: TJX Companies Inc is far larger — about 9.4× Ascendis Pharma A/S's market cap, and TJX Companies Inc pays a 1.27% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TJX | |
|---|---|---|
Market Cap | $17.74B | $167.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $168.41 |
52-Week Low | $163.32 | $121.35 |
Enterprise Value | $18.11B | $175.79B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TJX trades at $151.34, showing modest daily gains amid a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.19 versus $1.02 expected, and robust profitability metrics like a 61.25% ROE. Revenue growth is steady, climbing from $48.5B in 2022 to $56.4B in 2025, with further expansion projected. Recent news highlights TJX's resilience as a blue-chip retailer during market volatility, though technical indicators suggest near-term pressure.
The outlook for TJX remains positive based on fundamental strength and analyst optimism, with a consensus price target of $181.80 implying significant upside. Key opportunities include international expansion and same-store sales growth. Risks involve competitive retail pressures and macroeconomic sensitivity. Wall Street sentiment is overwhelmingly bullish, with 88% of analysts rating it a Buy, supporting a favorable long-term investment case despite short-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
